Andrew G. Polson

机构：Annexon Biosciences (United States), Instacart (United States) · ORCID：0000-0003-3289-6502

发表论文 208 篇 · 总被引 4406 次 · h-index 35

代表论文

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas (2023 · Blood · 被引 79)
T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing (2023 · Cancer Immunology Research · 被引 12)
Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma (2023 · Blood · 被引 1)
Abstract CT157: Phase 1 dose-escalation study of linclatamig, a LY6G6D×CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer (2025 · Cancer Research)
Data from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing (2024)
Supplementary Figure 1 from T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing (2024)